Analysis: Ajanta Pharma Limited

What does Ajanta Pharma Limited do?

• Ajanta Pharma is a specialty pharmaceuticals formulation company with Branded Generics business across India, Asia, Africa, and the US.
• Founded in 1979 by the Agrawal family, it is one of India's largest pharma firms by revenue.
• Operates seven manufacturing facilities in India, including two US FDA-approved and WHO cGMP-compliant sites.

• Branded Generics (74% of FY2025 revenue): India, Asia (Middle East, Southeast Asia), Africa.
• US Generics (23% of fy2025 revenue): ANDrogenic alopecia, CNS, and cardiovascular therapies.
• Africa Institutional (3% of fy2025 revenue): anti-malarial products distribution via multilateral agencies.
• New therapeutic areas: Gynaecology, Nephrology (launched in fy2025), and planned expansion into Latin America.

Growth thesis

Ajanta Pharma is a global branded generics formulator operating across India, the U.S., Asia, and Africa. The specific change defining the story from here is an upgraded FY27 revenue guidance to high teens, accelerating from mid-teens in FY26, driven by high double-digit growth in Asia and Africa branded generics. Over the next 12-24 months, the trajectory will be further shaped by GLP-1 semaglutide filings across 26 emerging markets via a Biocon partnership, with revenues expected to commence in FY27-28. Management is expanding the field force by roughly 400-450 representatives and deploying Rs. 400 crores in capacity capex to support this volume. EBITDA margins are guided to remain stable at 27% plus or minus 1%, with gross margins around 77%, despite a manufacturing facility transitioning out of its tax exemption period. The key execution watchpoint is successfully integrating the planned Rs. 1,000 crore inorganic acquisition without disrupting this stable margin profile.

Why is Ajanta Pharma Limited stock rising?

• Revenue growth guidance of high teens for FY27
• EBITDA margin guidance of 27% plus or minus 1% for FY27
• US generics business expected to post mid-single digit growth in FY27
• Asia branded generics targeted to deliver high double-digit growth in FY27
• GLP-1 semaglutide filings in emerging markets began in Q1 FY27, with Biocon partnership covering 26 countries; revenues expected to start from FY27-28

Research report

companyname: Ajanta Pharma Limited ticker: AJANTPHARM sector: Pharmaceutical formulations (specialty branded generics and US generics) Ajanta Pharma is a Mumbai-based pharmaceutical formulations company, incorporated in 1979, that makes and sells finished dosage forms across five distinct business verticals. The common thread is a focus on branded generics - branded, chronically-oriented prescription drugs sold in emerging markets - plus a separate US generic business and a small institutional ...

Catalysts

capex, regulatory approval, new product segment, acquisition inorganic

Growth guidance

FY27 revenue growth guided at high teens driven by India, U.S., Asia, and Africa business growth